» Articles » PMID: 16685409

Method for Efficient Transfection of in Vitro-transcribed MRNA into SK-N-AS and HEK293 Cells: Difference in the Toxicity of Nuclear EGFP Compared to Cytoplasmic EGFP

Overview
Journal Int J Mol Med
Specialty Genetics
Date 2006 May 11
PMID 16685409
Citations 4
Authors
Affiliations
Soon will be listed here.
Abstract

Here we report a method for efficient transfection of in vitro-transcribed mRNA into two different types of human adherent cells, the neuroblastoma cell line SK-N-AS, and the transformed kidney cell line HEK293. By using newly trypsinized adherent cells in suspension and Lipofectaminetrade mark 2000, we detected a transfection efficiency of 80-90% in both cell lines and a cell viability of 90% in SK-N-AS and 60% in HEK293, 24 h after transfection when using cytoplasmic enhanced green fluorescent protein (EGFP)-mRNA. We have evaluated the different effects of the generally used EGFP that mainly localizes to the cytoplasm and nuclear EGFP, where the nuclear EGFP are more toxic to the cells than the cytoplasmic EGFP. In order to develop a null experiment, we constructed a short non-functional mRNA including a nuclear localization signal and evaluated the concentrations at which mRNA encoding nuclear proteins can be added without a general toxicity, depending on the fact that the proteins are localized to the nucleus. For both SK-N-AS and HEK293 cells, a concentration of up to 100 ng mRNA in 10(5) cells, encoding a nuclear protein with no other function, did not affect the cells. For evaluation of the method, we screened four different human mRNAs, PDG, DFFA, CORT and PEX14, for their ability to affect cell proliferation in these cells. PEX14 was the only gene that significantly (p=0.03) reduced cell proliferation for both cell types, DFFA significantly (p=0.04) reduced cell proliferation in SK-N-AS but not in HEK293 cells. PGD and CORT did not have any effect on cell proliferation. We have developed an easy method for efficient delivery of in vitro-transcribed mRNA into the adherent cell lines, SK-N-AS and HEK293. This method is useful for a quick screening of how different genes affect cell proliferation.

Citing Articles

How mRNA therapeutics are entering the monoclonal antibody field.

Van Hoecke L, Roose K J Transl Med. 2019; 17(1):54.

PMID: 30795778 PMC: 6387507. DOI: 10.1186/s12967-019-1804-8.


Targeted gene therapy of the fusion gene controlled by the hSLPI gene promoter of human non-small cell lung cancer .

Hao S, Du X, Song Y, Ren M, Yang Q, Wang A Oncol Lett. 2018; 15(5):6503-6512.

PMID: 29731853 PMC: 5920898. DOI: 10.3892/ol.2018.8148.


Primary T cells for mRNA-mediated immunotoxin delivery.

Eggers R, Philippi A, Altmeyer M, Breinig F, Schmitt M Gene Ther. 2017; 25(1):47-53.

PMID: 28937681 DOI: 10.1038/gt.2017.87.


Zinc Finger Nucleases: Tailor-made for Gene Therapy.

Chou S, Leng Q, Mixson A Drugs Future. 2013; 37(3):183-196.

PMID: 24155503 PMC: 3801298. DOI: 10.1358/dof.2012.037.03.1779022.